Study | Dose | DLTs | Number of patients evaluable for DLT | Proportion of patients who experienced a DLT | P (DLT) for true dose toxicity curve |
---|---|---|---|---|---|
AZD3514 | 250 mg QD | 0 | 6 | 0% | 0% |
500 mg QD | 0 | 6 | 0% | 0% | |
1000 mg QD | 1 | 6 | 17% | 17% | |
1000 mg BID | 3 | 6 | 50% | 50% | |
2000 mg BID | 4 | 4 | 100% | 100% | |
AZD1208 | 120 mg QD | 0 | 3 | 0% | 0% |
240 mg QD | 0 | 3 | 0% | 0% | |
480 mg QD | 0 | 3 | 0% | 0% | |
700 mg QD | 1 | 4 | 25% | 25% | |
900 mg QD | 2 | 3 | 67% | 67% | |
AZD1480 | 15 mg BIDa | 0 | 4 | 0% | 0% |
20 mg BID | 1 | 5 | 20% | 20% | |
30 mg BID | 1 | 5 | 20% | 20% | |
35 mg BID | 2 | 3 | 67% | 67% | |
45 mg BID | 0 | 2 | 0% | 67% | |
AZD4877 | 2 mg twice weekly | 0 | 3 | 0% | 0% |
4 mg twice weekly | 0 | 3 | 0% | 0% | |
7 mg twice weekly | 0 | 3 | 0% | 0% | |
11 mg twice weekly | 0 | 6 | 0% | 0% | |
15 mg twice weekly | 2 | 2 | 100% | 100% |